{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:17:52Z","timestamp":1790864272372,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-related adverse events based on the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A disproportionality analysis was performed to assess the safety profile of mepolizumab based on the reports from the FAERS database between October 2015 and December 2022. Demographic information, the time to onset, the safety of long-term mepolizumab exposure as well as safety in pediatric patients were also investigated.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 736 significant preferred terms (PTs) were identified among the 13,497 mepolizumab-associated adverse events (AEs) reports collected from the FAERS database. The frequently reported AEs including dyspnea, fatigue, and headache were in line with drug instruction and previous studies. Unexpected significant AEs such as cough, malaise, and chest discomfort were also identified. Most AEs occurred within the first month after mepolizumab initiation. Pneumonia and wheezing were frequently reported in patients with long-term mepolizumab exposure as well as in the pediatric population.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our results were consistent with the observations in previous clinical and real-world studies. New and unexpected AE signals of mepolizumab were also identified. Close attention should be paid to the long-term safety of mepolizumab as well as safety in the pediatric population. Prospective studies are required for optimal use of mepolizumab.<\/jats:p>","DOI":"10.3389\/fphar.2023.1280490","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T14:44:32Z","timestamp":1701960272000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system"],"prefix":"10.3389","volume":"14","author":[{"given":"Huqun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongshu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuilian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"767999","DOI":"10.3389\/fphar.2021.767999","article-title":"Anaphylaxis associated with allergen specific immunotherapy, omalizumab, and dupilumab: a real world study based on the US Food and drug administration adverse event reporting system","volume":"12","author":"Bian","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/cea.14112","article-title":"Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis","volume":"52","author":"Charles","year":"2022","journal-title":"Clin. Exp. Allergy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/s2213-2600(17)30125-x","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"17534666211009398","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"00207-2022","DOI":"10.1183\/23120541.00207-2022","article-title":"Treatment with interleukin (IL)-5\/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD","volume":"8","author":"Drick","year":"2022","journal-title":"ERJ Open Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jaci.2019.08.005","article-title":"Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype","volume":"144","author":"Gupta","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/s2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","article-title":"Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system","volume":"93","author":"Harpaz","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/j.jaip.2022.04.014","article-title":"Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma - first initiators and switchers","volume":"10","author":"Hashimoto","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.jaip.2023.01.027","article-title":"Differences in hypersensitivity reactions to iodinated contrast media: analysis of the US Food and drug administration adverse event reporting system database","volume":"11","author":"Lin","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.07.024","article-title":"Mepolizumab in patients with severe asthma and comorbidities: 1-year REALITI-A analysis","author":"Liu","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract"},{"key":"B17","doi-asserted-by":"publisher","first-page":"858279","DOI":"10.3389\/fphar.2022.858279","article-title":"Anaplastic lymphoma kinase tyrosine kinase inhibitor-associated cardiotoxicity: a recent five-year pharmacovigilance study","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"00576-2021","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"212584","DOI":"10.7573\/dic.212584","article-title":"Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice","volume":"8","author":"Montero-P\u00e9rez","year":"2019","journal-title":"Drugs Context"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.rmed.2014.05.015","article-title":"Prevalence of severe childhood asthma according to the WHO","volume":"108","author":"Nordlund","year":"2014","journal-title":"Respir. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e09736","DOI":"10.1016\/j.heliyon.2022.e09736","article-title":"A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils","volume":"8","author":"Ohnishi","year":"2022","journal-title":"Heliyon"},{"key":"B23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/s2213-2600(17)30206-0","article-title":"Anti-interleukin 5 therapies in severe asthma","volume":"5","author":"Passalacqua","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/02770903.2019.1658208","article-title":"Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma","volume":"58","author":"Pertzov","year":"2021","journal-title":"J. Asthma"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3390\/cancers13081758","article-title":"Thromboembolic events with cyclin-dependent kinase 4\/6 inhibitors in the FDA adverse event reporting system","volume":"13","author":"Raschi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1169735","DOI":"10.3389\/fimmu.2023.1169735","article-title":"Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system","volume":"14","author":"Shu","year":"2023","journal-title":"Front. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.1007\/s00405-022-07389-5","article-title":"Hypereosinophilia management in patients with type 2 chronic rhinosinusitis treated with dupilumab: preliminary results","volume":"279","author":"Vinciguerra","year":"2022","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2023.2251382","article-title":"Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS)","author":"Zou","year":"2023","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1280490\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T14:44:34Z","timestamp":1701960274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1280490\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":30,"alternative-id":["10.3389\/fphar.2023.1280490"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1280490","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"article-number":"1280490"}}